Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Linear Formula:
H2NCH2C6H10CO2H
CAS Number:
Molecular Weight:
157.21
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
MDL number:
Beilstein/REAXYS Number:
2207452
grade
pharmaceutical primary standard
API family
tranexamic acid
manufacturer/tradename
USP
mp
>300 °C (lit.)
application(s)
pharmaceutical (small molecule)
format
neat
SMILES string
NC[C@H]1CC[C@@H](CC1)C(O)=O
InChI
1S/C8H15NO2/c9-5-6-1-3-7(4-2-6)8(10)11/h6-7H,1-5,9H2,(H,10,11)/t6-,7-
InChI key
GYDJEQRTZSCIOI-LJGSYFOKSA-N
Gene Information
human ... PLG(5340)
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Tranexamic acid USP Reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Tranexamic Acid Tablets
- Tranexamic Acid Injection
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Other Notes
Sales restrictions may apply.
Still not finding the right product?
Explore all of our products under Tranexamic acid
signalword
Warning
hcodes
Hazard Classifications
Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
target_organs
Respiratory system
Storage Class
11 - Combustible Solids
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Zhi-Jun Li et al.
European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society, 22(9), 1950-1957 (2013-05-10)
The present meta-analysis aimed at assessing the effectiveness and safety of tranexamic acid (TXA) in reducing blood loss and transfusion in spinal surgery. Systematic searches of all studies published through March 2012 were identified from PubMed, EMBase, Cochrane library, Science
Baohui Yang et al.
PloS one, 8(2), e55436-e55436 (2013-02-21)
Tranexamic acid (TXA) is well-established as a versatile oral, intramuscular, and intravenous (IV) antifibrinolytic agent. However, the efficacy of IV TXA in reducing perioperative blood transfusion in spinal surgery is poorly documented. We conducted a meta-analysis of randomized controlled trials
Chih-Hsiang Chang et al.
Clinical orthopaedics and related research, 472(5), 1552-1557 (2014-01-05)
Systemic tranexamic acid can decrease blood loss and rates of transfusion in patients undergoing total hip arthroplasty (THA). However, the efficacy of topical tranexamic acid in THA has only recently been characterized in a small number of studies. The purpose
Global Trade Item Number
| SKU | GTIN |
|---|---|
| 1672745-200MG | 04061833855683 |